Occupational studies: | | | Acute respiratory effects: |
48 | Pig farm workers | 40 | 180 ng/m3 | Cross-shift decline in FEV1 and MEF25 |
49 | Slaughter house workers | 23 | 20–1500 ng/m3 | Cross-shift decline in FEV1 and FVC; increased prevalence of respiratory symptoms |
50 | Animal feed workers | 119 | 29 ng/m3 | Cross-shift decline in MMEF and MEF50; cross-week decline in FEV1, MEF25, MMEF and MEF50 |
51, 52 | Fibreglass workers | 130 | 0.4–759 ng/m3 | Cross-shift decline in PEF and FEV1; increased amplitude of PEF; increased prevalence of respiratory symptoms and symptoms of fever, joint pains, and influenza-like symptoms |
53 | Potato processing workers | 61 | 21–56 EU/m3 | Cross-shift decline in FEV1 and MMEF |
54 | Potato processing workers | 97 | 534 EU/m3 | Cross-shift decline in PEF; increased prevalence of respiratory symptoms |
| | | | Chronic respiratory effects: |
55 | Cotton mill workers | 443 | 2–550 ng/m3 | Decline in FEV1; increased prevalence of chronic bronchitis and byssinosis |
56 | Pig farm workers | 183 | 130 ng/m3 | Decline in FEV1 and FVC; increased prevalence of respiratory symptoms |
57 | Cotton mill workers | 253 | 9–126 ng/m3 | Decline in FEV1 and FVC; increased prevalence of respiratory symptoms |
58 | Animal feed workers | 315 | 25 ng/m3 | Decline in FEV1,, FVC, PEF, MEF75, MEF50 |
59 | Cotton mill workers | 34 | 20–320 ng/m3 | Increase in bronchial hyperresponsiveness |
60 | Pig farm workers | 54 | 11332 EU/ m3 | Decline in FEV1 and FVC; increased prevalence of cough and chronic bronchitis |
61 | Grain workers | 410 | 2859 EU/ m3 | Decline in FEV1; increased prevalence of respiratory symptoms |
62† | Farm workers (pig farms/others) | 168/127 | 588/410 EU/m3 | Longitudinal decline in FEV1 and MMEF |
63† | Pig farm workers | 171 | 105 ng/m3 | Longitudinal decline in FEV1 |
64† | Grain and animal feed workers | 140 | 3.6–99.0 ng/m3 | Longitudinal decline in FEV1 and MMEF |
65†§ | Cotton mill workers | 366 | ∼3200 EU/m3 | Longitudinal decline in FEV1 and FVC |
| | | | |
Indoor studies: | | | |
20 | Adult asthmatic patients | 28 | 2.59 ng/mg | Decline in FEV1 and FEV1/FVC; increase in asthma medication and symptoms |
66 | Adult asthma (40)/rhinitis (29) patients | 69 | 1.78 ng/mg | Decline in FEV1, and FEV1/FVC; increase in asthma medication and symptoms |
67 | Children (50% with asthma) | 20 | 1–100 EU/mg | Increase in asthma medication and symptoms in asthmatic children |
22 | Children (50% with airway symptoms) | 148 | 24.9 EU/mg | Increased PEF variability in atopic children with asthma symptoms‡ |
68† | Infants | 499 | 100 EU/mg | Increased prevalence of wheeze during first year of life |